enGene (NASDAQ:ENGN) Shares Gap Down – Here’s What Happened

enGene Holdings Inc. (NASDAQ:ENGN) gapped down before the market opened on Monday . The stock had previously closed at $8.68, but opened at $8.06. enGene shares last traded at $7.67, with a volume of 351,577 shares.

Analyst Ratings Changes

ENGN has been the subject of a number of recent analyst reports. Citizens Jmp increased their price target on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 12th. Raymond James Financial restated a “strong-buy” rating and set a $27.00 target price on shares of enGene in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. Oppenheimer reissued an “outperform” rating and issued a $33.00 price target (up from $30.00) on shares of enGene in a research note on Wednesday, November 12th. Finally, UBS Group raised their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.29.

enGene Stock Performance

The company has a market capitalization of $519.31 million, a price-to-earnings ratio of -3.39 and a beta of -0.29. The company has a 50 day moving average price of $9.58 and a 200 day moving average price of $8.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). Equities research analysts predict that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC raised its holdings in enGene by 179.8% during the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after buying an additional 3,771,840 shares during the last quarter. Siren L.L.C. acquired a new position in shares of enGene during the fourth quarter valued at about $30,126,000. Braidwell LP bought a new stake in shares of enGene during the third quarter worth about $15,479,000. Janus Henderson Group PLC acquired a new stake in shares of enGene in the 4th quarter worth about $17,110,000. Finally, Cormorant Asset Management LP lifted its position in enGene by 72.1% in the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after acquiring an additional 1,676,405 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.